ixoberogene soroparvovec
AssetAlso called ADVM-022, AAV.7m8-aflibercept, Ixoberogene soroparvovec, Ixo-vec
Delivers an aflibercept gene to retinal cells for sustained inhibition of angiogenic growth factors.
- Stage
- Phase 3
- Modality
- Gene therapy
- Target
- Not known
- 5
- Indications
- 5
- Trials
- 1
- Developer
Indications
5Neovascular age-related macular degeneration
Phase 3, Active not recruiting, NCT06856577, clinicaltrials.gov, Oct 31, 2026
Wet age-related macular degeneration
Phase 3, Active not recruiting, NCT06856577, clinicaltrials.gov, Oct 31, 2026
Neovascular age-related macular degeneration (nAMD) wet AMD
Phase 2, Recruiting, NCT07630649, clinicaltrials.gov, Oct 31, 2026
2 more
In the full profile
- Owner and partners1
- Trials5
- Competitors11
- Signals2
Every asset’s record: target, stage, trials and the evidence behind it.